A Retrospective Chart Review Study Assessing Dosing Patterns and Outcomes of Ceritinib In Patients With ALK-Positive Non-Small Cell Lung Cancer In A Real-World Practice

Trial Profile

A Retrospective Chart Review Study Assessing Dosing Patterns and Outcomes of Ceritinib In Patients With ALK-Positive Non-Small Cell Lung Cancer In A Real-World Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Apr 2017 Results published in the Advances in Therapy
    • 19 Dec 2016 New trial record
    • 01 Nov 2016 Results published in the Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top